Articles | December 14, 2021
RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial of RL-007 These results support the progression of RL-007 to a double-blind, placebo-controlled Phase 2 trial focused on cognition atai Life Sciences (Nasdaq: ATAI)… Read More
Articles | December 13, 2021
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The NBI is a stock… Read More
Articles | December 9, 2021
TryptageniX will take a bioprospecting approach to develop patent-protected new chemical entities inaccessible through conventional chemical means The new platform company will focus on the generation of intellectual property around atai’s growing drug development pipeline spanning psychedelic and non-psychedelic compounds TryptageniX will also focus on novel and ecological biosynthetic production… Read More
Articles | November 29, 2021
Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced… Read More
Articles | November 15, 2021
Positive topline results from COMP360’s Phase 2b study RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4 Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase 2a and DemeRx’s Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort… Read More
Articles | November 8, 2021
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September… Read More
Articles | November 5, 2021
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November: Presentation details can be found below: Berenberg US CEO Conference 2021 Format: 1×1 Meetings… Read More
Articles | November 1, 2021
These data have given atai confidence to support an accelerated clinical development timeline. atai Life Sciences (Nasdaq: ATAI) (“atai”) today announced that it has observed encouraging interim data from the first 8-patient cohort of its Phase 2a trial, demonstrating potential pro-cognitive effects of its compound RL-007, a cholinergic, glutamatergic, and GABA type B receptor modulator, for Cognitive… Read More
Articles | October 19, 2021
atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences’ vision, to heal mental health disorders so that… Read More
Articles | October 11, 2021
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant… Read More